| Filed On | Filing |
|---|---|
| 29 Sep 2026 |
8-K: Regulation FD Disclosure
LEXINGTON, Mass., September 29, 2026, (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of... |
| 28 Sep 2026 |
8-K: Regulation FD Disclosure
LEXINGTON, Mass., September 28, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of ... |
| 16 Sep 2026 | EFFECT |
| 11 Sep 2026 | DEL AM |
| 10 Sep 2026 | S-3 |
| 08 Sep 2026 |
8-K: Other Events
LEXINGTON, Mass., September 8, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat ... |
| 20 Aug 2026 |
Form 4: Tanini Annita, Corp. Controller & VP, Finance
Sold 1,224 shares ($12.6K) |
| 20 Aug 2026 |
Form 4: Lerner Lorena Raquel, Chief Scientific Officer
Sold 3,568 shares ($36.7K) |
| 20 Aug 2026 |
Form 4: Cho Esther, Chief Legal Officer
Sold 4,485 shares ($46.2K) |
| 20 Aug 2026 |
Form 4: Newton Charles W., Director
Sold 551 shares ($5.68K) |
| 19 Aug 2026 |
Form 4: Bienaime Jean Jacques, Director
Bought 1,000 shares ($10.3K) |
| 18 Aug 2026 | 144 |
| 13 Aug 2026 |
Form 3: Tanini Annita, Corp. Controller & VP, Finance
Holds 46,368 shares of Common Stock |
| 03 Aug 2026 | 10-Q |
| 03 Aug 2026 | 8-K: Regulation FD Disclosure |
| 03 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 30 Jul 2026 | 8-K: Regulation FD Disclosure |
| 29 Jul 2026 | SCHEDULE 13G/A |
| 22 Jul 2026 | 8-K: Departure/Election of Directors or Officers; Compensation |
| 17 Jul 2026 |
Form 4: Bienaime Jean Jacques, Director
Bought 1,000 shares ($10.6K) |
Loading...
